SUMMARY ANSWER: This study demonstrated strong genetic effects on endometrial gene expression and some evidence for genetic regulation of gene expression in a menstrual cycle stage-specific manner.
Introduction
Human endometrium is essential for establishment and maintenance of pregnancy and plays a central role in female fertility. It is a dynamic tissue undergoing cyclical breakdown and regeneration across the menstrual cycle (Wilcox et al., 1999) . In association with histological and structural changes, gene expression and molecular signatures vary across the menstrual cycle (Talbi et al., 2006) . These dynamic changes require complex regulation of gene expression with changes in growth factors, cytokines, adhesion molecules, matrix metalloproteinases and enzymes for steroid hormone synthesis and metabolism across the menstrual cycle (Burney et al., 2007) .
Gene expression varies between individuals, and extensive studies show that the expression levels for many genes are under genetic control (Westra et al., 2013; GTEx Consortium, 2015) . These genetic effects, called expression quantitative traits loci (eQTLs), can have a substantial effect on variation in the expression of individual genes. The median proportion of variance explained is~15%, but can be as high as 100% for some genes (Powell et al., 2012a,b; Naranbhai et al., 2015) . The majority of cis-acting eQTL (~80%) are located within ±100 kb around the transcription start sites of the target gene, generally in non-coding regions of the genome (Powell et al., 2012a) . Therefore, eQTL studies are an essential approach to understanding tissue-specific gene regulation and identifying functional elements in the genome and their underlying biological variation (GTEx Consortium, 2013) .
Most eQTL studies so far have been performed with RNA isolated from lymphocytes or immortalized lymphoblasts/lymphocytes due to the difficulty in obtaining human tissue specimens. The GenotypeTissue Expression Project was designed to address this limitation by establishing a sample and data resource to enable studies into the relationship between genetic variation and gene expression in multiple human tissue types (GTEx Consortium, 2013 . The degree of eQTL sharing between tissues followed a U-shaped pattern, with either high tissue specificity (activity in a single tissue) or tissue ubiquity (activity in all nine tissues studied), suggesting the need for tissue-specific studies to identify the tissue-specific eQTLs (GTEx Consortium, 2013) . The current data release includes uterine samples from 70 donors, but they are mostly myometrial samples.
Here, we have comprehensively investigated changes in gene regulation occurring across the menstrual cycle. We subsequently, examined the genetic effects on gene expression in human endometrial tissue by mapping cis-eQTL, and performed a context-specific eQTL analysis to investigate if genetic effects on gene expression regulation act in a menstrual cycle stage-specific manner. We identified eQTLs for 198 unique genes and 5 cis-eQTLs with significant stage-by-genotype interaction. In addition, by separating our analysis of the expression levels of genes into those that were either ubiquitously or inconsistently expressed across the menstrual cycle, we present significant evidence of differential expression across the menstrual cycle stages for 1851 genes and a further 1037 genes were switched on or off at different stages the menstrual cycle.
Materials and Methods

Sample collection
We recruited 123 women of European ancestry attending clinics at the Royal Women's Hospital in Melbourne, Australia, as part of a larger study examining the role of genes linked with endometriosis risk. Only premenopausal women who were free from hormone treatment (in the 3 months prior to surgery) were included in this cohort. Detailed patient questionnaires, past and present clinical histories, pathology results and surgical notes were recorded for each participant. Endometrial tissue samples were collected by curettage from women with various gynaecological comorbidities including surgically diagnosed endometriosis (n = 91), ultrasound-confirmed adenomyosis (n = 5) and uterine fibroids (n = 10) ( Table I) . Whole blood samples were also collected from the same individuals. Endometrial cycle stage was determined following histological assessment by an experienced pathologist (Menstrual (M) = 4, Early Proliferative (EP) = 4, Mid-Proliferative (MP) = 51, Late Proliferative (LP) = 11, Early Secretory (ES) = 15, Mid-Secretory (MS) = 22 and Late Secretory (LS) = 16). Tissue samples were stored in RNAlater (Life Technologies, Grand Island, NY, USA) at −80°C until RNA extraction. The study was approved by the Human Research Ethics Committees of the Royal Women's Hospital, Melbourne and the QIMR Berghofer Medical Research Institute, and all women gave written consent.
RNA extraction
Total RNA was extracted from homogenized endometrial tissues using RNA lysis solution (RLT buffer) Unless stated otherwise data are percent (n).
Santa Clara, CA, USA) with all samples having high-quality RNA (RNA Integrity Number > 8), and concentrations were determined using the NanoDropND-6000.
Gene Expression Array
The study design and the data analyses are shown in Supplementary Figure S1 . Total RNA was amplified and converted to biotinylated cRNA using Ambion Illumina TotalPrep RNA amplification kit (Ambion, Thermo Fisher Scientific, Scoresby, VIC, Australia). Expression profiles were generated by hybridizing 750 ng of cRNA to Illumina Human HT-12 v4.0 Beadchips according to Illumina whole-genome gene expression direct hybridization assay guide (Illumina, Inc., San Diego, CA, USA). Briefly, 250 ng of total RNA were used to generate biotinylated cRNA, which was fragmented and hybridized to an Illumina whole-genome expression chip, HumanHT-12 v4.0 for 18 h at 58°C. Beadchips were then washed and stained and subsequently scanned to obtain fluorescence intensities. Samples were scanned using an Illumina iScan Reader. Samples were randomized across arrays and array positions.
Genotyping
Whole blood DNA samples were genotyped on HumanCoreExome chips (Illumina, Inc.). Standard quality control procedures were applied to data as outlined previously (Luong et al., 2013) . Briefly, single nucleotide polymorphisms (SNPs) with >5% missing rate, out of Hardy-Weinberg Equilibrium (P < 10
) in controls and Minor allele frequency (MAF) < 5% were excluded, and the remaining 299 186 autosomal SNPs carried forward for imputation. Un-genotyped SNPs were staged using HapiUR and imputed using 1000 Genomes V1.3 (hg19) with IMPUTE2 (Howie et al., 2009) . Raw imputed SNPs were filtered to remove any SNPs with low imputation quality (R 2 < 0.80) and with an MAF < 5%. After filtering, 8 613 031 SNPs remained for further analysis.
Gene expression normalization
The following normalization procedures were applied to the raw expression data for analysis. Pre-processing of data generated by the Illumina iScan Reader was carried out using Illumina GenomeStudio software (Illumina, Inc.). Pre-processing included: correction for chip background fluorescence effects, removal of outlier beads, computation of average bead signal and calculation of detection P values using negative controls present on the array. Any probe with a detection P value provided by GenomeStudio >0.05 was considered as not expressed for that given sample. In order to achieve a stabilized distribution across average expression levels, pre-processed transcript levels were transformed using a quantile adjustment across individuals, followed by scaling to log2. Further normalization was performed to allow expression levels to be compared across chips and genes. This was achieved fitting the following linear mixed model for each probe passing quality control:
where y is a vector of log-transformed probe expression levels, β is an unknown vector of fixed effects of batch, γ is an unknown vector of random effects (chip and well position within each chip) with known design matrix Z and ε is a vector of residual errors. The residuals from this model were standardized to z-scores and these were used in all further analyses.
Differential expression across menstrual stages
We sought to evaluate changes in gene expression across menstrual stages.
To avoid biasing our results with genes that were not expressed at certain stages of the menstrual cycle, we restricted our analysis to only those genes that were expressed in >90% of samples, leaving 15 226 probes, mapping to 12 329 unique RefSeq genes. We performed the differential expression analysis between stages of the menstrual cycle as defined in Talbi et al. (2006) , where MP samples were combined with the LP samples as proliferative (P) group (n = 62), and comparisons were made across successive cycle stages: P versus ES; ES versus MS and MS versus LS, using the eBayes method, which is implemented in the limma package. The moderated t-statistic applies an empirical Bayesian strategy to compute the gene-wise residual SDs. The resulting P values were corrected for multiple testing to control the false discovery rate (FDR) using the Benjamini-Hochberg method. We selected probes with a fold change >1.5 (corresponding to a 1.5 SDs) and a studywide FDR < 0.05 as differentially expressed.
On/off gene expression
To identify genes that were 'switched on/off' at different points in the menstrual cycles, we calculated the proportion of samples in the P (Exp P ) and ES (Exp ES ) groups for each of the 47 287 probes. The difference (Exp diff = Exp ES -Exp P ) enables the identification of genes that are commonly expressed at one stage in the menstrual cycle, and not expressed in the other stage. To determine the empirical sampling variance of Exp diff , we conducted permutation analysis by randomly assigning samples into two groups, with sample sizes equal to P and ES and calculating Exp diff for each probe. The mean and SD of Exp diff were recorded, and the process repeated 1000 times. From the permutations, we determined an empirical sampling variance of Exp diff , and identified genes that were 'switched on/off' at different stages of the menstrual cycles as those with observed Exp diff greater than ±5 SD from the empirical mean. We repeated the same analyses for ES versus MS and MS versus LS.
Pathway analysis
Pathway analysis was conducted using Ingenuity ® Pathway Analysis software (IPA ® , QIAGEN Redwood City, www.qiagen.com/ingenuity). Gene lists examined included those identified from the differential expression analysis and the 'on/off' analysis. Significant canonical pathways were derived using internal right-tailed Fisher exact tests and P values adjusted using the Benjamini-Hochberg multiple correction method. A pathway was considered significant at the P < 0.01 threshold.
eQTL analysis
All 123 individuals included in the eQTL analysis were of European ancestry (Supplementary Figure S2) . We performed cis-eQTL analysis for 15 226 probes (expressed in >90% of samples) mapping to 12 329 unique RefSeq genes, where the cis region was defined at ±250 kb from the probe start position. The relationship between SNP genotypes and normalized expression levels was tested using a linear model (-assoc command) with the assumption of an additive allele effect. Case/control status for surgically confirmed endometriosis was fitted as covariate with a fixed effect in the model. For each eQTL that reached a conservative study-wide significance level of P < (0.05/(average number of SNPs in the region × 15 226 probes tested)), i.e. P < 1 × 10
, we performed a conditional and joint association analysis (Yang et al., 2012) to identify secondary independent eQTL. Post hoc tests were performed to compare cases of fibroids with other samples to ensure that the results were not confounded by the small number of confirmed cases with fibroids.
Context-specific eQTL analysis
We tested for genotype-by-stage interactions for 13 cis-eQTL for genes that were differentially expressed between different stages of the menstrual cycle using the following model:
where y denotes the observed normalized expression level of a probe, μ the mean expression level across the sample, β 1 the regression coefficient of the genotype, β 2 the regression coefficient of stage (classified as either secretory or P) and β 3 is the regression coefficient of the interaction between genotype and stage. We ensured that the genotype-by-stage interaction term was not due to a secondary eQTL in linkage disequilibrium (LD) with the primary eQTL using conditional analysis on the primary eQTL.
Overlap with blood eQTLs
We assessed the overlap of endometrial tissue and blood eQTLs, identified by the Consortium for the Architecture of Gene Expression (CAGE) analysis, consisting of expression samples measured for 2765 (Lloyd-Jones et al., 2017) . As the power to detect eQTL is partly a function of the discovery sample size, comparison of eQTL from two studies of different sample sizes is expected to downwardly bias the estimate of the true proportion overlapping due to the lower power of the smaller study (McKenzie et al., 2014) . We addressed this problem using a method presented by Ding et al. (2010) that adjusts for the difference in sample sizes, and thus statistical power, to re-estimate eQTL overlap expected under the scenario of equal sample size. Briefly, and in the notation of Ding et al. (2010) , to estimate the power-adjusted expected overlap, we started with the lists of eQTL identified in the endometrial (i) and CAGE (j) studies. eQTLs are determined based on significance threshold, α, which corresponds to an FDR of 0.05. From these lists, we determined the observed percentage of eQTL overlapping between studies (π raw ). However, because both eQTL lists are inevitably incomplete, π raw will be an underestimate of the true level of overlap, π . As i is of smaller sample size than j, then the power to detect 'true' overlapping eQTL will be lower. The power-adjusted expected overlap in significant eQTL (π adjusted ) is calculated as
where power i is determined from the effect sizes of the overlapping eQTL, the sample size and α i ,
power i_raw is defined as the statistical power of study j with a sample size matching study i to detect all identified eQTL from study j. Since CAGE was the largest study by far, we used this sample to estimate power i_raw in the following way: from CAGE we sampled two mutually exclusive and independent datasets (j 1 and j 2 ), with the sample size of both j 1 and j 2 equal to that of study i. eQTLs are identified in j 1 and j 2 assuming significance threshold of study-wide FDR of 0.05, and power i_raw is calculated as the proportions identified in j 1 that are also significant in j 2 . Using Equations (1) and (2), we calculated π adjusted , which is the estimated cis-eQTL overlap between endometrial and blood tissue.
Overlap with trait-/disease-associated variants
Trait-associated GWAS SNPs were downloaded in May 2016 from the NHGRI Catalogue of Published GWAS using the default P value threshold of 10 −5 (Welter et al., 2014) . The degree of overlap between endometrial tissue eQTLs and GWAS loci was based upon a minimum LD r 2 > 0.7 between the eSNP and GWAS SNP in the 1000 Genome reference panel (Genomes Project et al., 2015) . SNPs that were not identified in populations of European descent were excluded.
Results
Changes in gene expression across the menstrual cycle
A number of genes are expressed in differing proportions of sample has important consequences for interpretation of differential gene expression and for the analysis of eQTLs. To better understand changes in gene expression across the menstrual cycle, we conducted separate analyses for genes that were ubiquitously expressed across the cycle, and for genes that displayed inconstant expression across the cycle. We compared the differential expression of the P to early secretory (ES) stage samples for 15 226 probes expressed in >90% of the samples. After correction for multiple testing, we identified 733 genes that were significantly up-regulated in the ES stage and 855 genes that were significantly down-regulated in the ES stage of the cycle (Fig. 1A) . Details of all differentially expressed genes are given in Supplementary  Table S1 . For genes significantly up-or down-regulated in the ES stage relative to the P stage of the menstrual cycle, the significant pathways from IPA ® pathway analysis were dominated by those associated with cell signalling and cell cycling, and included 'Oestrogen-mediated Table SII) .
From the on/off gene expression analysis (see 'Methods' section), we identified strong evidence of gene switching across the menstrual cycle. We used permutations to determine the empirical sampling variance of differences in the proportions of samples expressing each gene and the number of probes with a Exp diff >3 SDs between the menstrual cycle stages was 12-fold higher than expected by chance (Supplementary Table SIII) . We identified 197 genes that were predominately expressed in individuals sampled in the ES stage and 354 genes that were predominately expressed in individuals sampled in the P stage of the menstrual cycle (Supplementary Table SIV ). The significant pathways in P versus ES are listed in Supplementary Table SV. The analysis of differential expression between ES versus midsecretory (MS) and MS versus late secretory (LS) identified 87 genes that were significantly up-regulated between the ES and MS stages and 119 genes significantly up-regulated between the MS and LS stages of the cycle (Fig. 1B and C) . Likewise, we identified 31 genes significantly down-regulated between the ES and MS stages and 134 genes significantly down-regulated between the MS and LS stage of the cycle (Fig. 1B and C) . Details of all differentially expressed genes are given in Supplementary Table SVI Table SX) , with genes including the well-known transcription factor transforming growth factor beta 2 (TGFB2). We compare differentially expressed, and 'on/off' genes with those previously published from a study with a smaller sample size [2], and found a good concordance across stage comparisons (Fig. 2 , Supporting Note 1, Table SXI ).
Identifying cis-eQTLs
We analysed 15 226 probes for associations with SNP genotypes located within a ±250 kb window from the probe start site. At a Bonferroni significance threshold of P < 1.0 × 10 −7
, we identified 18 595 cis expression regulatory SNPs (eSNPs). Using conditional and joint association mapping, these eSNPs corresponded to 211 independent eQTL, mapping to 198 unique genes ( Fig. 3A and Supplementary Table SXII) . The relationships between genotypes of SNPs and gene expression levels of the top five cis-eQTLs for genes CHURC1, ZP3, IPO8, CPNE1, ERAP2 are shown in Fig. 3B . The median proportion of variance in gene expression explained by the 211 cis-eQTL is 5.3%, although the top eSNP for genes with the largest eQTLs explained more than 40% of the variation in gene expression. Details and summary statistics for the top 20 most significant cis-eQTLs with unique genes are given in Table II . While we have used a conservative statistical threshold to identify eQTL for further analyses, Figure 1 The differential expression analysis across menstrual cycle stages of genes that were expressed in >90% of samples (n = 15 226 probes).
Probes significantly (FDR < 0.05) up-regulated with log2-fold change smaller than −0.58 (i.e. fold change >1.5) in P stage, ES, MS and LS were represented as blue, orange, red and green dots, respectively. The top 10 significantly differentially expressed genes from each group were labelled on the plot. The significant P value cut-off without multiple testing correction was represented by the grey line. FDR, false discovery rate; P, proliferative; ES, early secretory; MS, mid-secretory; LS, late secretory. Figure 2 The Venn diagrams showing the number of regulated genes across the menstrual cycle and the number of genes shared between the previous study (Talbi et al., 2006) and this study. we appreciate the likelihood of incurring false negative results through this approach. Indeed, at a study-wide false discovery threshold of 0.05, we identify 311 independent eQTL. These results and all the Supplementary tables are publicly available to browse or download at http://reproductivegenomics.com.au/shiny/endo_eqtl/. We did not observe any significant effects of endometriosis case/controls status or presence of fibroids on the expression of significant eQTLs.
We assessed the overlap with eQTL identified in a large (n = 2765) blood tissue analysis (Lloyd-Jones et al., 2017) by matching on identical transcripts and eSNP with LD (r 2 ) > 0.9 in 1000 Genomes data. Only six endometrial eQTLs (3%), identified at a study-wide significance level, overlapped with those identified in blood (Supplementary Table SXIII) , however, this low percentage of overlap is almost certainly a function of the considerably lower power of our endometrial cohort. To account for this, we employed a statistical approach (Ding et al., 2010) to estimate the expected overlap, under the scenario of equal statistical power between the two studies. After accounting for differences in statistical power, the estimate of the expected proportion of blood cis-eQTL that would be identified had this endometrial study been of equal size, π adjusted , was 26%. It is important to note that the method used to estimate the adjusted overlap assumes that the distributions of eQTL effect sizes are similar for overlapping and non-overlapping eQTL.
We next sought to identify the degree of overlap between endometrial tissue eQTLs and GWAS loci, based upon a minimum LD r 2 > 0.7 between the eSNP and GWAS SNP in the 1000 Genome reference panel (Genomes Project et al., 2015) . Of the 211 independent eQTLs, 23 overlapped with one or more GWAS loci, representing a total of 41 independent phenotypes. A full summary of overlapping loci is given in Supplementary Table SXIV.
Context-specific local genetic variants
The endometrium is a unique tissue type and, as we have shown, gene expression levels vary considerably across the menstrual cycle. It is unclear whether genetic effects on gene expression regulation are constrained to menstrual cycle stages. To investigate cycle stageinteracting eQTLs, we performed a context-specific eQTL analysis for 13 cis-eQTLs (10 eQTLs in P versus ES, 1 eQTL in ES versus MS and 2 eQTLs in LS versus MS) that were identified for genes that were significantly differentially expressed. Genotype-by-stage interactions occur when the effect of genotype on expression differs across different stages of the menstrual cycle. For example, the genetic effects on expression may be present in only one stage and may have different magnitudes of effect across stages. After multiple testing corrections (0.05/13 = 3.8 × 10 −3 ), we identified five eQTLs with significant stage-by-genotype interactions (Table III and Supplementary Figure S3 ). The strongest stage interaction was the eQTL for C10ORF33 (PYROXD2) (Illumina probe ID: ILMN_1684497), with the sentinel eSNP rs2296438. The effects of homozygosity for the [C] allele at rs2296438 were significantly greater during the P stage when the expression levels were higher (P = 2.01 × 10 −4 ) ( Fig. 4 and Table II ).
Discussion
We analysed genetic effects on gene expression in the endometrium. Our study is the first to examine effects across the menstrual cycle and shows genetic effects on multiple genes and genotype by cycle-stage interactions for some eQTLs. We identified 198 genes under the control of local genetic effects. After conditional analysis of the top eQTLs, there was no evidence for secondary signals for any of these genes. Genes under genetic control regulate diverse cellular functions. Among the genes with the strongest evidence for cis-eQTLs in human endometrium were Churchill Domain Containing 1 (CHURC1), Importin 8 (IPO8) and Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). CHURC1 is a transcriptional activator that mediates Fibroblast Growth Factor signalling during neural development. It is one of several genes down-regulated in early onset of severe pre-eclampsia (Sun et al., 2009 The eQTLs with significant interaction between stage of the cycle and genotype are highlighted in grey.
suggested as a reference gene for expression studies in endometrium (Ayakannu et al., 2015) , but our data suggest that it should be used with caution as differences in allele frequency of the key SNP in small samples could bias results. ERAP2 is a gene encoding an aminopeptidase that cleaves precursors to generate or destroy MHC class I binding peptide (Cifaldi et al., 2012) and regulates innate immune and inflammatory responses. Alterations of ERAP function might lead to inadequate immune responses and have been shown to associate with the development of various diseases including ovarian and breast cancers (Fruci et al., 2008) and pre-eclampsia (Johnson et al., 2009) . Other genes under genetic control, including Aryl Hydrocarbon Receptor Nuclear Translocator encodes a protein that binds to ligand bound Aryl Hydrocarbon receptor and promotes xenobiotic metabolism (Girolami et al., 2016) and Caspase Recruitment Domain Family Member 8 that negatively regulates IL1B secretion (Agostini et al., 2004) and apoptosis (Razmara et al., 2002) . We looked for interactions between genotype and cycle stage and found that the effects of genotype were similar across different stages of the menstrual cycle for most genes exhibiting eQTL. However, there was significant evidence for stage by genotype interactions for five genes, with one being an interesting target for reproductive biology. The eSNP rs252895 on chromosome five regulates expression of the gene C5ORF35 (which is also known as Su(var)3-9, enhancer-ofzeste, trithorax (SET) domain-containing 7/9 (SET7/9)), which has reported methyltransferase activity on various proteins, including oestrogen receptor (ER)-α (Subramanian et al., 2008) and androgen receptor (Gaughan et al., 2011) . Down-regulation of SET7/9 has been shown to impair recruitment of ER to its target genes and attenuate oestrogen-driven transcriptional response in breast cancer cells (Subramanian et al., 2008; Takemoto et al., 2016) . ER-α expression is critical for the menstrual cycle and endometrial physiology (Mylonas et al., 2004 (Mylonas et al., , 2007 Li et al., 2014) and a decrease in ER-α expression in the MS phase leads to defects in uterine receptivity . Our results showed that the magnitude of allelic effect of rs252895 on SET7/9 expression was significantly greater in secretory stage endometrium. Future studies comparing eQTL maps in endometrium and epigenetic marks will be helpful to examine the role of DNA methylation in genetic effects on gene expression.
Multiple methods have been developed for missing value imputation, but the choice of method has a strong impact on detection of Figure 4 Genotype modulates the gene expression differences across to menstrual cycle stages in the endometrium. The blue boxplots represent the P samples and orange boxplots represent the ES samples. differentially expressed genes (Oh et al., 2011) and it remains unclear how missing value imputation methods affect downstream analyses such as biomarker detection, classification and gene cluster analysis. By separating our analysis of the expression levels of genes into those that were either ubiquitously or inconsistently expressed across the menstrual cycle, we were able to produce a comprehensive catalogue of changes in gene regulation between the defined stages of the cycle. Our results showed significant evidence of differential expression across the menstrual cycle for 2161 probes for 1851 genes and a further 1075 probes for 1037 genes were expressed in different proportions of samples across the menstrual cycle. The results are comparable to previous studies reporting gene expression in human endometrium (Talbi et al., 2006; Burney et al., 2007) . We compared our lists of differentially regulated genes with the lists of genes reported by Talbi et al. as differentially regulated across the P, ES, MS and LS stages of the cycle (Talbi et al., 2006) . There was good concordance in regulated genes between the studies and more importantly, the genes showing differential expression in both studies are all regulated with the same directions of effect. This provides evidence of cross-study validation despite differences in experimental design, array platform and data analysis.
The IPA analysis of our differentially expressed and 'On/Off' genes identified pathways consistent with known endometrial activity, as well as novel genes and gene pathways not previously examined in relation to endometrial function. For example, the transition from P to ES phases highlighted three genes involved with fatty acid activation (solute carrier family 27 member 2 (SLC27A2)), SLC27A6 (expression of both family members largely restricted to the P phase) and acyl-CoA synthetase long-chain family member 5 (ACSL5, expression largely restricted to the ES phase). These enzymes play key roles in lipid biosynthesis and fatty acid degradation and therefore contribute to cell and tissue metabolism, membrane structure, intracellular signalling and production of bioactive lipid mediators and hormones (such as prostaglandins) (Calder, 2015) . To our knowledge, the specific activities of SLC27A2 and SLC27A6 have not been examined in cycling endometrium; however, ACSL5 mRNA and protein are highly expressed in endometrial epithelium (Gassler et al., 2005; Uhlen et al., 2010) . The data in the current study illustrate the broad knowledge about endometrial function and regulation that has already been accumulated, but highlight the extensive gaps in knowledge that still remain. The comprehensive gene lists can be used for further hypothesis-generation for researchers aiming to elucidate normal and abnormal endometrial function.
Genetic variants influencing complex disease are often located outside of gene coding sequences within regulatory regions and influence disease susceptibility though effects on RNA transcription (Westra et al., 2013; Fung et al., 2015) . Endometrium is likely the target tissue for endometriosis (Zondervan et al., 2016) , and genetic studies in endometriosis have identified eight well-replicated genomic regions associated with increased disease risk (Nyholt et al., 2012; Rahmioglu et al., 2014) . We compared our lists of genes with significant eQTLs in endometrium with potential candidate genes in each of the eight endometriosis risk-associated regions. There was one genome-wide significant cis-eQTL in endometrium for the long non-coding RNA LINC00339/HSPC157 at chromosome 1p36.12 with SNPs associated with endometriosis risk, also reported in our study and the study of Burrows et al. (2016) . Suggestive evidence for a cis-eQTL for vezatin (VEZT) on chromosome 12 reported previously with this sample set is supported by strong evidence for a similar eQTL for VEZT in RNA samples from blood (Holdsworth-Carson et al., 2016) . We also looked at overlap between cis-eQTL in endometrium and trait associations from the GWAS catalogue (Welter et al., 2014) . Of the 23 eQTL that overlapped GWAS loci, most represent single hits. The eQTL for ATP13A1 with rs2304130, which is also an eQTL in blood (Westra et al., 2013) , overlapped with GWAS 'hits' for body mass index, LDL cholesterol and triglycerides. The eQTL for LINC00339 at chromosome 1p36 also overlapped with GWAS hits for bone mineral density and epithelial ovarian cancer as previously reported (Rivadeneira et al., 2009; Kuchenbaecker et al., 2015) . No other eQTL overlapped with disease associations directly related to endometrial biology.
An important limitation of the present study was the relatively modest sample size compared with studies in accessible tissues like whole blood, although the sample size is larger than most studies in endometrium. The modest sample limits the statistical power to detect eQTL and we expect to detect many more eQTLs with larger samples. We controlled for FDR by using a stringent multiple testing correction and conservative threshold for declaring significant effects. It estimates that there is a 5% chance of one false positive among the identified cis-eQTLs and sample for differential expression in this study. The study was not powered to identify trans-eQTLs. Another limitation is that endometrial tissue can only be collected at surgery from women attending gynaecology clinics. We included the presence or absence of endometriosis as a covariate in the model. There were limited data on other known pathologies. Given the substantial changes in gene expression across the menstrual cycle for many genes, substantially larger sample sizes will be needed to provide better power to detect cis-eQTLs and cycle stage-specific and diseasespecific effects.
Gene expression microarray data provide limited information on individual transcripts (Sun and Hu, 2013) . RNA-seq data would allow us to study the effects of genetic variants on RNA splicing and novel transcripts. Recent evidence identified genetic effects on splicing with little or no effect on gene-level expression that mediate the biological consequences of disease-associated variants (Li et al., 2016) . The use of whole endometrial tissue in this study also has limitations because the tissue is made up of multiple cell types and there are changes in cellular composition and cell activity across the cycle (Smith, 2002) . Statistical methods have been developed to predict cellular composition in whole blood from large samples with data on both cell composition and gene expression (Westra et al., 2015) , but these datasets are not available for endometrium. Single cell RNA-seq methods may overcome some of these limitations in future to properly account for variation in cell composition at various stages of menstrual cycle. Nevertheless, understanding how the numerous eQTLs identified in this study impact on endometrial function may help explain normal variation in cyclic and uterine bleeding patterns among women and help to elucidate different endometrial-related disorders.
In summary, genetic differences influence expression of numerous genes with diverse functions in endometrium. Many genes show substantial changes in expression across the menstrual cycle to support a functional role in preparation for implantation and our results also demonstrate interactions between genotype effects and stage of the cycle for some genes. Greater understanding of the role of genetic effects on gene expression is important for functional studies in endometrium and the biological consequences of endometrial-related diseases.
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